Madrigal Pharmaceuticals (MDGL) Amortization of Deferred Charges (2022 - 2026)

Madrigal Pharmaceuticals (MDGL) has 5 years of Amortization of Deferred Charges data on file, last reported at $449000.0 in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 2.98% year-over-year to $449000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 13.53% decrease from a year earlier, with the FY2025 full-year figure at $1.6 million, down 23.22% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $449000.0, down from $468000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for MDGL reached as high as $753000.0 in Q4 2023 and fell as low as $178000.0 in Q2 2022.
• Historically, Amortization of Deferred Charges has averaged $459562.5 across 5 years, with a median of $458500.0 in 2025.
• Across the five-year window, Amortization of Deferred Charges jumped 211.24% in 2023 and sank 35.99% in 2024, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $306000.0 in 2022, then jumped by 146.08% to $753000.0 in 2023, then sank by 35.99% to $482000.0 in 2024, then slipped by 2.9% to $468000.0 in 2025, then declined by 4.06% to $449000.0 in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $449000.0 in Q1 2026, $468000.0 in Q4 2025, and $329000.0 in Q3 2025.